Letter to Liu et al.'s “Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome”

Letter to Liu et al.'s “Efficacy of Exenatide on weight loss, metabolic parameters and... Dear Editors,I was intrigued to see the recent trial of Liu et al reporting the benefits of exenatide over metformin in terms of weight loss and pregnancy rate in women with polycystic ovary syndrome. I am writing to clarify the discrepancies between the trial as registered and the trial as reported in the manuscript. According to the trial registration on the Chinese Clinical Trial Registration Site (ChiCTR‐IIR‐16008084), the trial was a three‐armed trial for exenatide, metformin or spironolactone. The study as reported only includes two arms, one with exenatide with eventual crossover to metformin the second to metformin alone. What happened to the spironolactone arm and where did the crossover design originate? The authors also report clinical pregnancy rates on treatment. This is not listed as one of the objectives of the study on the clinical trial registration site. Similarly, the inclusion and exclusion criteria as listed on the registration site make no mention of patients seeking pregnancy or screening for fertility factors in the patient or couple. In fact one of the exclusion criteria reads “Also exclude patients who could not take effective contraceptive measures through the study,” The method of randomization and the means to maintain allocation concealment are not noted in the published manuscript. Providing these would help external reviewers assess the quality of the trial. Finally, I note that the trial was registered after recruitment had begun. Can the authors provide an explanation for this lapse? Thank you very much for clarification of these questions.REFERENCELiu X, Zhang Y, Zheng S‐Y, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol. (Oxf). 2017;87:767–774. https://doi.org/10.1111/cen.13454. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Endocrinology Wiley

Letter to Liu et al.'s “Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome”

Free
1 page

Loading next page...
1 Page
 
/lp/wiley/letter-to-liu-et-al-s-efficacy-of-exenatide-on-weight-loss-metabolic-j0svCGvhHO
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Ltd
ISSN
0300-0664
eISSN
1365-2265
D.O.I.
10.1111/cen.13474
Publisher site
See Article on Publisher Site

Abstract

Dear Editors,I was intrigued to see the recent trial of Liu et al reporting the benefits of exenatide over metformin in terms of weight loss and pregnancy rate in women with polycystic ovary syndrome. I am writing to clarify the discrepancies between the trial as registered and the trial as reported in the manuscript. According to the trial registration on the Chinese Clinical Trial Registration Site (ChiCTR‐IIR‐16008084), the trial was a three‐armed trial for exenatide, metformin or spironolactone. The study as reported only includes two arms, one with exenatide with eventual crossover to metformin the second to metformin alone. What happened to the spironolactone arm and where did the crossover design originate? The authors also report clinical pregnancy rates on treatment. This is not listed as one of the objectives of the study on the clinical trial registration site. Similarly, the inclusion and exclusion criteria as listed on the registration site make no mention of patients seeking pregnancy or screening for fertility factors in the patient or couple. In fact one of the exclusion criteria reads “Also exclude patients who could not take effective contraceptive measures through the study,” The method of randomization and the means to maintain allocation concealment are not noted in the published manuscript. Providing these would help external reviewers assess the quality of the trial. Finally, I note that the trial was registered after recruitment had begun. Can the authors provide an explanation for this lapse? Thank you very much for clarification of these questions.REFERENCELiu X, Zhang Y, Zheng S‐Y, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol. (Oxf). 2017;87:767–774. https://doi.org/10.1111/cen.13454.

Journal

Clinical EndocrinologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off